Medable has launched a new patient-first offering that aids life sciences firms in boosting patient access, enrolment, and retention in oncology trials. 

An end-to-end suite, the offering comprises pre-built and verified decentralised clinical trial (DCT) applications such as Total Consent and Televisit, a wide-ranging eCOA oncology library, and protocol design consultation.

It also provides a single entry point for sites, sponsors, and patients.

To expand access, diversity, and retention in trials, the solution aids patients who are receiving rigorous cancer treatments to take part remotely in the at-home setting, as well as on-site. 

It also keeps patients occupied while streamlining the collection of data for sites and sponsors. 

Prompt notifications and reminders aid in guaranteeing compliance while the real-time reporting functionality of the company boosts patient- and caregiver-friendly ePROs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This approach makes tracking and offering responses to new toxicity and tolerability signals easy. 

By integrating patient trial data with real-world data to capture key endpoints, tokenisation simplifies data collection after the trial for lifetime follow-up.

Medable Therapeutic Area Solutions vice-president Musaddiq Khan said: “The reinvigorated Cancer Moonshot initiative coupled with the FDA’s emphasis on diversity in clinical research is driving an urgent need to improve access to cancer trials. 

“Our DCT offering is designed around the core needs of oncology trials while enabling optionality to improve access and the patient experience. 

“Meeting patients where they are while offering better insight and data to site and study teams improves the experience for everyone and, subsequently, retention.”

This February, the company launched the Medable Partner Network, merging a varied ecosystem of technology, service, data, site and direct-to-patient partners that collaborate to fast-track DCT deployment.